Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + carboplatin + cisplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JS001 + carboplatin + cisplatin + etoposide is a combination chemo-immunotherapy regimen developed by Shanghai Junshi Biosciences for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of toripalimab (JS001), a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, combined with etoposide and a platinum agent (either carboplatin or cisplatin). By blocking the PD-1/PD-L1 pathway, toripalimab restores T-cell anti-tumor activity, while the chemotherapy components provide direct cytotoxic effects and potentially enhance immunogenicity. This combination was approved by China's NMPA in June 2024 based on the Phase 3 EXTENTORCH trial, which demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone.
- Brand names
- Tuoyi
- Other names
- JS001 + carboplatin + cisplatin + etoposidetoripalimab plus platinum-etoposide
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on toripalimab + carboplatin + cisplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + carboplatin + cisplatin + etoposide.